Trial Profile

CANadian Study in Patients With Wet AMD, Evaluating the Efficacy and Safety of Switching From Intravitreal Aflibercept to RanIbizumab

Status: Withdrawn prior to enrolment

Phase of Trial: Phase IV

Latest Information Update: 17 Feb 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranibizumab (Primary)
Indications Choroidal neovascularisation; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms CANARI
Sponsors Novartis Pharmaceuticals

Most Recent Events

14 Feb 2017 Planned initiation date changed from 1 Dec 2015 to 1 Mar 2016.
14 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
23 Dec 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com